Badura Lori, Swanson Terri, Adamowicz Wendy, Adams Jessica, Cianfrogna Julie, Fisher Katherine, Holland Janice, Kleiman Robin, Nelson Frederick, Reynolds Linda, St Germain Kristin, Schaeffer Eric, Tate Barbara, Sprouse Jeffrey
Comparative Physiology and Medicine, Pfizer Global Research and Development, MS 8220-4178, Groton, CT 06340, USA.
J Pharmacol Exp Ther. 2007 Aug;322(2):730-8. doi: 10.1124/jpet.107.122846. Epub 2007 May 14.
Casein kinase Iepsilon (CKIepsilon) is an essential component of the biological clock, phosphorylating PER proteins, and in doing so regulating their turnover and nuclear entry in oscillator cells of the suprachiasmatic nucleus (SCN). Although hereditary decreases in PER phosphorylation have been well characterized, little is known about the consequences of acute enzyme inhibition by pharmacological means. A novel reagent, 4-[3-cyclohexyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine (PF-670462), proved to be both a potent (IC(50) = 7.7 +/- 2.2 nM) and selective (>30-fold with respect to 42 additional kinases) inhibitor of CKIepsilon in isolated enzyme preparations; in transfected whole cell assays, it caused a concentration-related redistribution of nuclear versus cytosolic PER. When tested in free-running animals, 50 mg/kg s.c. PF-670462 produced robust phase delays when dosed at circadian time (CT)9 (-1.97 +/- 0.17 h). Entrained rats dosed in normal light-dark (LD) and then released to constant darkness also experienced phase delays that were dose- and time of dosing-dependent. PF-670462 yielded only phase delays across the circadian cycle with the most sensitive time at CT12 when PER levels are near their peak in the SCN. Most importantly, these drug-induced phase delays persisted in animals entrained and maintained in LD throughout the entire experiment; re-entrainment to the prevailing LD required days in contrast to the rapid elimination of the drug (t(1/2) = 0.46 +/- 0.04 h). Together, these results suggest that inhibition of CKIepsilon yields a perturbation of oscillator function that forestalls light as a zeitgeber, and they demonstrate that pharmacological tools such as PF-670462 may yield valuable insight into clock function.
酪蛋白激酶Iε(CKIε)是生物钟的重要组成部分,可使PER蛋白磷酸化,从而调节其在视交叉上核(SCN)振荡器细胞中的周转和核内进入。虽然遗传性PER磷酸化降低已得到充分表征,但关于通过药理学方法急性抑制该酶的后果知之甚少。一种新型试剂4-[3-环己基-5-(4-氟苯基)-3H-咪唑-4-基]-嘧啶-2-胺(PF-670462)在分离的酶制剂中被证明是一种有效的(IC50 = 7.7±2.2 nM)且具有选择性(相对于另外42种激酶>30倍)的CKIε抑制剂;在转染的全细胞试验中,它导致核与胞质PER的浓度相关重新分布。在自由活动的动物中进行测试时,50 mg/kg皮下注射PF-670462在昼夜节律时间(CT)9给药时产生强烈的相位延迟(-1.97±0.17小时)。在正常明暗(LD)条件下给药然后释放到持续黑暗中的同步化大鼠也经历了相位延迟,这些延迟与给药剂量和时间相关。PF-670462在整个昼夜周期中仅产生相位延迟,最敏感的时间是CT12,此时SCN中PER水平接近峰值。最重要的是,这些药物诱导的相位延迟在整个实验中持续存在于同步化并维持在LD条件下的动物中;与药物的快速消除(t1/2 = 0.46±0.04小时)相比,重新同步到当前的LD需要数天时间。总之,这些结果表明抑制CKIε会导致振荡器功能的扰动,从而阻止光作为授时因子,并且它们证明像PF-670462这样的药理学工具可能会对生物钟功能产生有价值的见解。